...
机译:咪唑的设计与合成咪唑吡嗪伊克34抑制剂,用于治疗突变体MyD88 L265P扩散大B细胞淋巴瘤
China Pharmaceut Univ State Key Lab Nat Medicines Ctr Drug Discovery 24 Tongjiaxiang Nanjing;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Shanghai 201203 Peoples R China;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Shanghai 201203 Peoples R China;
China Pharmaceut Univ State Key Lab Nat Medicines Ctr Drug Discovery 24 Tongjiaxiang Nanjing;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Shanghai 201203 Peoples R China;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Shanghai 201203 Peoples R China;
China Pharmaceut Univ Dept Med Chem 24 Tongjiaxiang Nanjing 210009 Peoples R China;
Univ Chinese Acad Sci 19A Yuquan Rd Beijing 100049 Peoples R China;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Shanghai 201203 Peoples R China;
Chinese Acad Sci Shanghai Inst Mat Med State Key Lab Drug Res Shanghai 201203 Peoples R China;
China Pharmaceut Univ State Key Lab Nat Medicines Ctr Drug Discovery 24 Tongjiaxiang Nanjing;
lnterleukin-1 receptor associated kinase 4; Imidazol1; 2-6pyridazine; Diffuse large B-cell lymphoma; Drug design; Antitumor agents;
机译:咪唑的设计与合成咪唑吡嗪伊克34抑制剂,用于治疗突变体MyD88 L265P扩散大B细胞淋巴瘤
机译:发现一系列5-氮杂喹唑啉,作为口服有效的伊拉克4抑制剂,靶向MYD88(L265P)突变体弥漫性大B细胞淋巴瘤
机译:白细胞介素-1受体相关激酶4(IRAK4)的发现和优化用于处理突变体MyD88 L265p弥漫性大B细胞淋巴瘤
机译:弥漫性大B细胞淋巴瘤的病理分析及中西医临床治疗
机译:潜在的脂肪酸合酶抑制剂的建模指导合成,用于治疗弥漫性大B细胞淋巴瘤
机译:R-CHOP治疗MYD88 L265P突变在弥漫性大B细胞淋巴瘤中的高频率和预后价值
机译:MyD88 L265P突变和CDKN2A损失是亚型中枢神经系统的早期突变事件弥漫性大B细胞淋巴瘤